-
Most Recent
Search Results
240 results for icgn
Don’t Get Suckered Into Ocugen Stock
OCGN stock has gone crazy amid a partnership to develop a Covid-19 vaccine. The problem is there’s little evidence it will actually work.
Ocugen Stock Is a Speculative Covid-19 Vaccine Bet
OCGN stock is a speculative bet. FDA approval of Covaxin would boost the shares. However, the firm’s revenue potential is limited.
Ocugen Investors Are Missing the Obvious Signs of Failure
Initially, the stupendous rise of OCGN stock may give you the case of the FOMOs. But don’t let that emotions guide you as Ocugen is…
The Excitement Around Ocugen Is Irrational
OCGN stock surged on news of a coronavirus vaccine, but its fundamentals do not support its stock price, making it another speculative bet.
Ocugen Likely Can’t Get a Boost From the FDA Until 2023
It would likely take until mid-2023 for the FDA to approve Covaxin. By that time, the shot could be obsolete. Sell OCGN stock.
Ocugen Stock Looks Poised to Take a Tumble Right Here
After WHO granted Covaxin a limited Emergency Use Listing, many institutions and hedge funds are likely to sell or short OCGN stock.
Ocugen’s Facing a Major Uphill Climb Without FDA Approval
The quick FDA approval of Ocugen’s Covid-19 vaccine is fading with every passing day. As a result, OCGN stock is down 17% in the past…
Why the Coronavirus May Have Disrupted Ocugen
In analyzing the science behind OCGN stock, the innovation is quite profound. However, it’s this very platform that is under serious scrutiny thanks to the…
FDA’s Vaccine Attitude, New Data Don’t Bode Well for Ocugen Stock
The FDA’s recent warning that it could reject some applications for EUAs from vaccine makers does not portend well for Ocugen’s aspirations. OCGN stock remains…
A Robinhood Pop Doesn’t Make Ocugen Stock a Smart Investment
A disappointment throughout most of this year, OCGN stock recently shot higher. It’s very possible that enthusiastic but misguided speculators are behind this move.
OCGN Stock: The Big Covaxin News That Has Ocugen Rallying Today
Ocugen’s Indian vaccine development partner reported better-than-expected results from its local Covid-19 vaccine trials. OCGN stock has been on a roller-coaster ride on every Covaxin…
The Math Simply Doesn’t Favor Ocugen Stock
Because of the dynamics of the new normal, troubled names like OCGN stock continue to attract speculative interest. Perhaps some math will finally dissuade these…
Ocugen Surged on Its Covid Vaccine Emergency Approval in India
OCGN stock has suffered as a Covid-19 vaccine latecomer, but news that Covaxin won emergency approval in India sent shares soaring.
Think Twice Before You Roll the Dice on Ocugen Stock
OCGN stock may spike once again on positive news, but investors’ best best is to steer clear of it at this point in time.
Why Ocugen Stock Is Just a Gamble Right Now
A recent stock surge might make OCGN stock tempting. But it’s a poor choice given Ocugen’s lack of predictable profitability and the general uncertainty around…
3 Retail Stocks to Buy Off the Rack
Retail stocks, especially apparel stocks, are having a bad start to the year. But there are still some worth buying, like these three hidden gems.
Ocugen Stock Is Down but Not Out
Keep in mind it works better as a long-term play than a short-term trade. But if you handle possible future volatility, you may want to…
Beware: Ocugen Is a Near $2 Billion Company That Has No Revenue
While the market obviously loves Ocugen’s pivot to addressing the Covid-19 pandemic, the reality is that OCGN stock doesn’t come anywhere close to deserving its…
Avoid Ocugen Stock as Science and the Markets Clash
OCGN stock makes an attractive speculative case because of the underlying company’s potential to address rare eye diseases. Still, this is an opportunity that only…
For Biopharma Ocugen, Think Speculation In Small Doses
While Ocugen is unprofitable and in bad need of cash, OCGN stock could soar if its eye disease therapies see clinical success.
Ocugen Stock May Have One More Rally in It Before It’s Over
Long-term prospects for OCGN stock remain unclear, but its Covid-19 catalyst could fuel another spike in the short-term.
9 – 10 of 240 results
